Aminothiazole inhibitors of cyclin dependent kinases

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 417/12 (2006.01) A61K 31/426 (2006.01) A61K 31/427 (2006.01) A61P 29/00 (2006.01) A61P 31/18 (2006.01) A61P 35/00 (2006.01) C07D 277/54 (2006.01) C07D 417/14 (2006.01)

Patent

CA 2309551

Compounds of formula (I) and pharmaceutically acceptable salts thereof. As used in formula (I), and throughout the specification, the symbols have the following meanings: R1 and R2 are independently hydrogen, fluorine or alkyl; R3 is aryl or heteroaryl. The compounds of formula (I) are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis.

On décrit des composés de la formule (I) et des sels pharmaceutiquement acceptables desdists composés. Dans ladite formule, les symboles, tels qu'ils apparaissent dans tout le descriptif, ont la signification suivante: R1 et R2 sont indépendamment hydrogène, fluor ou alkyle; R3 est aryle ou hétéroaryle. Ces composés sont des inhibiteurs de la protéine kinase et conviennent pour le traitement ou la prévention de maladies prolifératives, telles que le cancer, l'inflammation ou l'arthrose.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Aminothiazole inhibitors of cyclin dependent kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminothiazole inhibitors of cyclin dependent kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminothiazole inhibitors of cyclin dependent kinases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1498871

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.